ATI-2341, pepducin targeting the C-X-C chemokine receptor type 4 (CXCR4), is an allosteric agonist activating the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization.
|Solubility (25°C)||DMSO 100 mg/mL|
Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Related CXCR Products|
|AMD 070 hydrochloride
AMD 070 hydrochloride is a selective, orally active chemokine receptor (CXCR4) antagonist with an IC50 value of 13 nM.
DOTA-CXCR4-L is a CXCR4 targeting peptide.
Pentixafor is a peptide that targets CXCR4.
CXCR4-IN-1 is a CXCR4 inhibitor (IC50: 20 nM).
|CCR7 antagonist 1
CCR7 antagonist 1 is a dual CXCR2 (IC50 of 11.02 μM) and CCR7 (IC50 of 0.43 μM) antagonist.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.